Skip to main content
Top

Targeted Oncology

Issue 2/2014

Content (10 Articles)

Review

Market access of cancer drugs in European countries: improving resource allocation

Kim Pauwels, Isabelle Huys, Minne Casteels, Katelijne De Nys, Steven Simoens

Original Research

Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine

Daniela Laura Papademetrio, Victoria Cavaliere, Tania Simunovich, Susana Costantino, María Dolores Campos, Tomás Lombardo, Claudio Marcelo Fader Kaiser, Élida Álvarez

Original Research

Anti-leukemic response of a NSAID, tolfenamic acid

Robert M. Sutphin, Sarah F. Connelly, Chris M. Lee, Umesh T. Sankpal, Don Eslin, Moeez Khan, Hima Pius, Riyaz Basha

Original Research

Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases

Johnny Kao, Chien-Ting Chen, Charles C. L. Tong, Stuart H. Packer, Myron Schwartz, Shu-hsia Chen, Max W. Sung

Original Research

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT

M. Di Bartolomeo, F. Pietrantonio, F. Perrone, K. F. Dotti, A. Lampis, C. Bertan, E. Beretta, L. Rimassa, C. Carbone, P. Biondani, R. Passalacqua, S. Pilotti, E. Bajetta

Original Research

A novel system enhancing the endosomal escapes of peptides promotes Bak BH3 peptide inducing apoptosis in lung cancer A549 cells

Nanjing Lin, Wenyun Zheng, Linfeng Li, Hui Liu, Tianwen Wang, Ping Wang, Xingyuan Ma

Erratum

Erratum to: Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer

Luís León, Roberto García-Figueiras, Cristina Suárez, Antonia Arjonilla, Javier Puente, Blanca Vargas, Maria José Méndez Vidal, Carmen Sebastiá

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine